|

Precision Cancer Therapy in Rare Cancers

RECRUITINGPhase 2Sponsored by Oslo University Hospital
Actively Recruiting
PhasePhase 2
SponsorOslo University Hospital
Started2025-03-20
Est. completion2033-11-30
Eligibility
Age16 Years – 99 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06119789

Summary

Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers. In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.

Eligibility

Age: 16 Years – 99 YearsHealthy volunteers accepted
Inclusion Criteria:

* ECOG 0-2,
* identified biomarker,
* reasonable biochemistry

Exclusion Criteria:

* ECOG 3-5
* serious other diseases

Conditions2

CancerRare Malignant Neoplasm

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.